Article

Epicardium-Derived Cardiac Mesenchymal Stem Cells Expanding the Outer Limit of Heart Repair

William Penn University, Filadelfia, Pennsylvania, United States
Circulation Research (Impact Factor: 11.09). 03/2012; 110(7):904-6. DOI: 10.1161/RES.0b013e31825332a3
Source: PubMed

ABSTRACT The epicardium is derived from the proepicardial organ, a source of multipotent progenitor cells. Epicardium contribution to the developing coronary vasculature and to cardiac interstitial cells has been established. Studies over the past several years have suggested that epicardium-derived cells can adopt cardiomyocyte and vascular smooth muscle fates and can contribute to cardiac repair when activated by injury.(1,2) Recently, Chong et al(3) have provided a detailed characterization of a population of epicardium-derived multipotent cardiac progenitor cells (cCFU-Fs). These cells, which do not arise from the bone marrow, neural crest, or myocardium, resemble mesenchymal stem cells (MSCs) and may participate in cardiac development, homeostasis, and repair.(3)

1 Follower
 · 
100 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular research is progressing on many fronts, as highlighted in the collection of Reviews in this issue of the JCI. MicroRNAs that regulate cardiac function have been implicated in cardiac disorders, and efforts to develop therapeutic antagomirs are underway. The genetic bases of several cardiac disorders, including cardiomyopathies that cause heart failure and channelopathies that underlie cardiac arrhythmias, have been elucidated. Genetic testing can identify asymptomatic individuals at risk, potentially leading to effective preventative measures. Growing evidence supports the role of chronic inflammation in atherosclerosis, providing new opportunities for therapeutic intervention. For heart failure, recent work suggests that cardiac regeneration using stem/progenitor cells, gene transfer, new drugs that restore normal Ca2+ cycling, and agents that reduce reperfusion injury following myocardial infarction are all viable new approaches to managing disease. Cumulatively, it seems likely that the clinical advances emerging from ongoing research will, in the foreseeable future, reduce the number of deaths in the industrialized world from cardiovascular disease.
    The Journal of clinical investigation 01/2013; 123(1):6-10. DOI:10.1172/JCI67541 · 13.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite many innovative advances in cardiology over the past 50 years, heart disease remains a major killer. The steady progress that continues to be made in diagnostics and therapeutics is offset by the cardiovascular consequences of the growing epidemics of obesity and diabetes. Truly innovative approaches on the horizon have been greatly influenced by new insights in cardiovascular development. In particular, research in stem cell biology, the cardiomyocyte lineage, and the interactions of the myocardium and epicardium have opened the door to new approaches for healing the injured heart.
    The Journal of clinical investigation 01/2013; 123(1):71-4. DOI:10.1172/JCI62884 · 13.77 Impact Factor
  • Source
    Circulation Research 12/2014; 115(12):e71-8. DOI:10.1161/CIRCRESAHA.114.305567 · 11.09 Impact Factor